Pharmacy Daily | Scheduling changes?

THE Therapeutic Goods Administration is proposing a raft of scheduling changes to the current Poison Standard. The changes include rescheduling benzodiazepines from Schedule 4 to Schedule 8; as well as a proposal to exempt from scheduling diclofenac when presented as a 140 mg or less diclofenac transdermal drug delivery system; and plans to to reschedule preparations containing 1% or less hydrocortisone and hydrocortisone acetate when combined with antifungal substances for dermal use from Schedule 3 to Schedule 2. The changes also include a proposal to reschedule nabiximols from Paragraph 3 of the Appendix D to Paragraph 1 of the Appendix D; and plans to reschedule oseltamivir for the treatment and prevention of influenza type A and type B from Schedule 4 to Schedule 3; as well as a proposal to include lisdexamfetamine in Schedule 8. The proposed changes have now been referred for scheduling advice to relevant expert advisory committees, and are also up for public comment. Those wishing to make comment are encouraged to submit thoughts in electronic format (Word or PDF) to SMP@health.gov.au by 17 January 2013. For details see www.tga.gov.au.

---

The above article was sent to subscribers in Pharmacy Daily's issue from 29 Nov 12
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 29 Nov 12